T H E N I H C A T A L Y S T | M A Y J U N E 2006 |
|
Building 33 Dedicated May 2BIODEFENSE
AND EMERGING
INFECTIOUS DISEASES
|
|
![]() |
|
On
Deck: (left to right) Rep.
C.W. Bill Young (R.-Fla.), for whom the new building is named, is joined
by NIH Director Elias Zerhouni and NIAID Director Anthony Fauci alongside
the Building 33 commemorative plaque, which reads: |
The
vision of the building dedicated on the NIH campus in May 2006
started taking shape in the fall of 2001it rose from incinerated buildings
and powdery envelopes in the New York and Washington, D.C., areas.
Accelerating
research to defend against bioterrorism was a driving force behind the concept
of Building 33.
But
its developmentlike that of the NIAID biodefense research agenda and strategic
plan, issued in early 2002was firmly grounded in the context of emerging
and re-emerging infectious diseases.
The
science does not turn on whether the involved pathogens "are naturally
occurring or deliberately perpetrated,"NIAID Director Anthony
Fauci observed in a speech during the ceremony to dedicate the brick, glass,
and steel structure where that
research will now be concentrated.
The
new facility, Fauci noted, will enable the "gathering under one roof of
a critical mass of researchers currently scattered in many buildings around
this campus," whose work with a variety of respiratory viruses and bacteria
will benefit from the "creative synergies" fostered by the new infrastructure.
The
building houses animal care-areas, conference rooms, offices, and biosafety
level 2 and 3 laboratoriesadding another 14,300 square foot of BSL-3 lab
space to NIAID's current 4,700 square feet. Researchers working in the BSL-3
labs will wear special protective equipment and receive specialized training
in state-of-the-art techniques for handling BSL-3 pathogens.
The
new center will consolidate and expand NIAID's existing research programs on
Respiratory
viruses (such as influenza and avian flu)
Respiratory
bacteria, such as multidrug-resistant TB and anthrax)
Insect-borne
viruses (such as West Nile and dengue)
Immunology
of infectious diseases
Development
of vaccines for infectious diseases
A new program focusing on innate immunity will also be established in Building 33. Fauci noted that pathogens requiring BSL-4 facilities will not be studied in the new center.
![]() |
![]() |
![]() |
Building
33, NIH Director Elias
Zerhouni noted with pride, emerged "on time, on budget,"
but had obstacles to overcome, not the least of which was the concern
of the surrounding Bethesda community about potential environmental risks.
Detailed explanations of the building's design, security, and safeguards
were not quite convincing enough, Zerhouni recalled."But then I told
them that I guarantee that Tony Fauci will have his office right in the
middle of that buildingand that won the day!"
|
Flanked
by NIAID Director Anthony Fauci and NIH Director Elias Zerhouni, Rep.
C.W. Bill Young receives gifts of gratitude for his "unwavering support
for biomedical research"an artist's rendering of Building 33
and a certificate commemorating the day's event
|
The
latest addition to the NIH research complex, Building 33 will house about
250 laboratory, administrative, and support staff within its four stories
and 12 intramural research laboratories. Construction was begun in November
2003 and completed in December 2005; move-in is anticipated throughout
the summer of 2006. |